The evolving role of bone-conserving therapy in patients with breast cancer

Seminars in Oncology

Volumn 37, Issue SUPPL., 2010, Pages

  Brufsky, Adam M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; DENOSUMAB; IBANDRONIC ACID; LETROZOLE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 77955451755     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.06.002     Document Type: Article

References (70)

1. M. Garcia, A. Jemal, and E.M. Ward, et al. Global cancer facts & figures, 2007 2007 American Cancer Society Atlanta, GA
2. M.F. Gnant, B. Mlineritsch, and G. Luschin-Ebengreuth, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group J Clin Oncol. 25 2007 820 828
3. H. Ding, and T.S. Field Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen? Cancer Treat Rev 33 2007 506 513
4. P. Hadji Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Crit Rev Oncol Hematol 69 2009 73 82
5. C.L. Shapiro, J. Manola, and M. Leboff Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer J Clin Oncol 19 2001 3306 3311
6. R.E. Coleman Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 2001 165 176
7. K.P. Weinfurt, L.D. Castel, Y. Li, J.W. Timbie, G.A. Glendenning, and K.A. Schulman Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions Med Care 42 2004 164 175
8. K.P. Weinfurt, Y. Li, and L.D. Castel, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer Ann Oncol 16 2005 579 584
9. G.N. Hortobagyi, R.L. Theriault, and A. Lipton, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate Protocol 19 Aredia Breast Cancer Study Group J Clin Oncol 16 1998 2038 2044
10. P.P. Major, R.J. Cook, A. Lipton, M.R. Smith, E. Terpos, and R.E. Coleman Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity BMC Cancer 9 2009 272
11. M. Trinkaus, C. Simmons, J. Myers, G. Dranatisaris, and M. Clemons Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting Support Care Cancer 18 2010 197 203
12. P. Major The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy Oncologist 7 2002 481 491
13. F. Lumachi, A. Brunello, A. Roma, and U. Basso Medical treatment of malignancy-associated hypercalcemia Curr Med Chem 15 2008 415 421
14. P. Hadji, J.J. Body, and M.S. Aapro, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss Ann Oncol 19 2008 1407 1416
15. J. Robbins, A.K. Aragaki, and C. Kooperberg, et al. Factors associated with 5-year risk of hip fracture in postmenopausal women JAMA 298 2007 2389 2398
16. F. Saad, A. Lipton, R. Cook, Y.M. Chen, M. Smith, and R. Coleman Pathologic fractures correlate with reduced survival in patients with malignant bone disease Cancer 110 2007 1860 1867
17. B.E. Hillner, J.N. Ingle, and R.T. Chlebowski, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 2003 4042 4057
18. R.W. Carlson, D.C. Allred, and B.O. Anderson, et al. Breast cancer Clinical practice guidelines in oncology J Natl Compr Canc Netw 7 2009 122 192
19. A. Brufsky, N. Bundred, and R. Coleman, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole Oncologist 13 2008 503 514
20. A.M. Brufsky Cancer treatment-induced bone loss: pathophysiology and clinical perspectives Oncologist 13 2008 187 195
21. A.M. Brufsky, L.D. Bosserman, and R.R. Caradonna, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results Clin Breast Cancer 9 2009 77 85
22. H. Eidtmann, R. de Boer, and N.J. Bundred, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receving adjuvant letrozole: 36-month results of the ZO-FAST study Ann Oncol www.annonc. oxfordjournals.org Epub 2010 May 5, doi: 10.1093/annonc/mdq217
23. N. Schenk, A. Llombart, and A. Frassoldati, et al. The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let) [abstract] Eur J Cancer Suppl (Meeting Abstracts) 5 2007 186 187
24. L. Vehmanen, T. Saarto, I. Elomaa, P. Makela, M. Valimaki, and C. Blomqvist Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients The effect of adjuvant clodronate treatment Eur J Cancer 37 2001 2373 2378
25. P.D. Delmas, R. Balena, E. Confravreux, C. Hardouin, P. Hardy, and A. Bremond Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study J Clin Oncol 15 1997 955 962
26. S.L. Hines, B.A. Mincey, and J.A. Sloan, et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer J Clin Oncol 27 2009 1047 1053
27. Shapiro CL, Halabi S, Hars V, et al. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809. Paper presented at: 44th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30; Chicago, IL.
28. D.L. Hershman, D.J. McMahon, and K.D. Crew, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer J Clin Oncol 26 2008 4739 4745
29. M. Gnant, B. Mlineritsch, and G. Luschin-Ebengreuth, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy Lancet Oncol 9 2008 840 849
30. G.E. Fuleihan, M. Salamoun, and Y.A. Mourad, et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial J Clin Endocrinol Metab 90 2005 3209 3214
31. T. Saarto, L. Vehmanen, I. Elomaa, M. Valimaki, P. Makela, and C. Blomqvist The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer Br J Cancer 84 2001 1047 1051
32. C.B. Confavreux, A. Fontana, J.P. Guastalla, F. Munoz, J. Brun, and P.D. Delmas Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole Prevention with bisphosphonates Bone 41 2007 346 352
33. S.L. Greenspan, A. Brufsky, and B.C. Lembersky, et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial J Clin Oncol 26 2008 2644 2652
34. Van Poznak C, Hannon R, Clack G, et al. Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE). Poster presented at: 31st Annual San Antonio Breast Cancer Symposium; 2008 December 10; San Antonio, TX.
35. S. Singh, J. Cuzick, and R. Edwards, et al. Effect of anastrozole on bone mineral density after one year of treatment: results from the bone sub-study of the International Breast Cancer Intervention Study (IBIS-II) [abstract] Breast Cancer Res Treat (Meeting Abstracts) 106 2007 S9
36. J.E. Lester, D. Dodwell, and O.P. Purohit, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer Clin Cancer Res 14 2008 6336 6342
37. G.K. Ellis, H.G. Bone, and R. Chlebowski, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 2008 4875 4882
38. Llombart A, Frassoldati A, Paija O, et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Paper presented at: ASCO 2009 Breast Cancer Symposium; 2009 Oct. 8; San Francisco, CA.
39. N. Pavlakis, R.L. Schmidt, and M. Stockler Bisphosphonates for breast cancer (review) Cochrane Database Syst Rev 3 2005 CD003474
40. G.N. Hortobagyi, R.L. Theriault, and L. Porter, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases N Engl J Med 335 1996 1785 1791
41. J.J. Body, I.J. Diel, and M.R. Lichinitser, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 14 2003 1399 1405
42. J.J. Body, I.J. Diel, and R. Bell, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer Pain 111 2004 306 312
43. B. Kristensen, B. Ejlertsen, M. Groenvold, S. Hein, H. Loft, and H.T. Mouridsen Oral clodronate in breast cancer patients with bone metastases: a randomized study J Intern Med 246 1999 67 74
44. A.H.G. Paterson, T.J. Powles, J.A. Kanis, E. McCloskey, J. Hanson, and S. Ashley Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer J Clin Oncol 11 1993 59 65
45. M. Tubiana-Hulin, P. Beuzeboc, and L. Mauriac, et al. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases] Bull Cancer 88 2001 701 707
46. J.R. Green Preclinical pharmacology of zoledronic acid Semin Oncol 29 2002 3 11
47. M. Aapro, P.A. Abrahamsson, and J.J. Body, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 2008 420 432
48. L. Costa, and P.P. Major Effect of bisphosphonates on pain and quality of life in patients with bone metastases Nat Clin Pract Oncol 6 2009 163 174
49. J.J. Body, I.J. Diel, and M. Lichinitzer, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies Br J Cancer 90 2004 1133 1137
50. N. Kohno, K. Aogi, and H. Minami, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial J Clin Oncol 23 2005 3314 3321
51. A. Lipton, R. Cook, and F. Saad, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid Cancer 113 2008 193 201
52. Stopeck A, Body JJ, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study [oral presentation]. Presented at: ECCO 15-34th ESMO Multidisciplinary Congress; 2009 20 September; Berlin, Germany.
53. D. Santini, B. Vincenzi, and G. Avvisati, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients Clin Cancer Res 8 2002 1080 1084
54. D. Santini, B. Vincenzi, and G. Dicuonzo, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients Clin Cancer Res 9 2003 2893 2897
55. D. Santini, F. Martini, and M.E. Fratto, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients Cancer Immunol Immunother 58 2009 31 38
56. R. Aft, M. Naughton, and K. Trinkaus, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial Lancet Oncol 11 2010 421 428
57. Lin A, Park J, Melisko M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; 2007 December 13; San Antonio, TX.
58. Rack BK, Jueckstock J, Genss E-M, et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; 2007 December 13; San Antonio, TX.
59. Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Poster presented at: 31st Annual San Antonio Breast Cancer Symposium; 2008 December 10; San Antonio, TX.
60. I.J. Diel, E.F. Solomayer, and S.D. Costa, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment N Engl J Med 339 1998 357 363
61. T. Powles, A. Paterson, and E. McCloskey, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] Breast Cancer Res 8 2006 R13
62. A. Jaschke, G. Bastert, E.F. Solomayer, S. Costa, F. Schuetz, and I.J. Diel Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up [abstract] J Clin Oncol (Meeting Abstracts) 22 2004 9
63. I.J. Diel, A. Jaschke, and E.F. Solomayer, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up Ann Oncol 19 2008 2007 2011
64. T. Saarto, L. Vehmanen, C. Blomqvist, and I. Elomaa Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients [abstract] J Clin Oncol (Meeting Abstracts) 22 2004 8
65. T.C. Ha, and H. Li Meta-analysis of clodronate and breast cancer survival Br J Cancer 96 2007 1796 1801
66. M. Gnant, B. Mlineritsch, and W. Schippinger, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 2009 679 691
67. R.E. Coleman, M.C. Winter, and D. Cameron, et al. The effects of adding zoldronic acid to neoadjuvant chemotherapy on tumor response: exploratory evidence for direct anti-tumour activity in breast cancer Br J Cancer 102 2010 1099 1105
68. C.I. Ripamonti, M. Maniezzo, and T. Campa, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates The experience of the National Cancer Institute of Milan Ann Oncol 20 2009 137 145
69. S. Khosla, D. Burr, and J. Cauley, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 2007 1479 1491
70. R. Weitzman, N. Sauter, and E.F. Eriksen, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006 Crit Rev Oncol Hematol 62 2007 148 152